Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer.
In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40 mg/m2 on day 1) and vinorelbine (20 mg/m2 on days 1 and 8) every 4 weeks. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed (four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.
Rimassa
Lorenza
L
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano MI, Italy. lorenza.rimassa@humanitas.it
Carnaghi
Carlo
C
Garassino
Isabella
I
Salvini
Piermario
P
Ginanni
Valeria
V
Gullo
Giuseppe
G
Morenghi
Emanuela
E
Santoro
Armando
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012074:Remission Induction; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D008081:Liposomes; D014747:Vinblastine; D004317:Doxorubicin; D000077235:Vinorelbine